Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bearish Engulfing | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Up 3 Days in a Row | Strength | -9.26% | |
| Upper Bollinger Band Touch | Strength | -9.26% | |
| 20 DMA Support | Bullish | -5.25% | |
| Bullish Engulfing | Bullish | -0.58% | |
| Crossed Above 20 DMA | Bullish | -0.58% | |
| Earnings Movers | Other | -0.58% | |
| Fell Below 20 DMA | Bearish | 7.52% |
| Alert | Time |
|---|---|
| 20 DMA Support | 1 day ago |
| 60 Minute Opening Range Breakdown | 1 day ago |
| Down 1 ATR | 1 day ago |
| Rose Above Upper Bollinger Band | 1 day ago |
| 1.5x Volume Pace | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 11/11/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Solid Tumor Cancers Immune Checkpoint Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.97 |
| 52 Week Low | 1.36 |
| Average Volume | 761,390 |
| 200-Day Moving Average | 2.21 |
| 50-Day Moving Average | 2.82 |
| 20-Day Moving Average | 3.47 |
| 10-Day Moving Average | 3.45 |
| Average True Range | 0.29 |
| RSI (14) | 54.95 |
| ADX | 36.13 |
| +DI | 23.39 |
| -DI | 16.63 |
| Chandelier Exit (Long, 3 ATRs) | 3.10 |
| Chandelier Exit (Short, 3 ATRs) | 3.71 |
| Upper Bollinger Bands | 3.84 |
| Lower Bollinger Band | 3.10 |
| Percent B (%b) | 0.45 |
| BandWidth | 21.24 |
| MACD Line | 0.20 |
| MACD Signal Line | 0.23 |
| MACD Histogram | -0.0294 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.21 | ||||
| Resistance 3 (R3) | 4.29 | 4.11 | 4.08 | ||
| Resistance 2 (R2) | 4.11 | 3.91 | 4.07 | 4.04 | |
| Resistance 1 (R1) | 3.77 | 3.79 | 3.68 | 3.69 | 3.99 |
| Pivot Point | 3.59 | 3.59 | 3.55 | 3.55 | 3.59 |
| Support 1 (S1) | 3.25 | 3.39 | 3.16 | 3.17 | 2.87 |
| Support 2 (S2) | 3.07 | 3.27 | 3.03 | 2.82 | |
| Support 3 (S3) | 2.73 | 3.07 | 2.78 | ||
| Support 4 (S4) | 2.65 |
